Corrigendum to “Exploring new mechanisms of imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction” [Biomed. Pharmacother. 175 (2024) 116755]
Yilin Li,
Nengjun Lou,
Xiaojing Liu,
Xianghua Zhuang,
Shihong Chen
Affiliations
Yilin Li
Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan 250033, China
Nengjun Lou
Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan 250033, China
Xiaojing Liu
Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan 250033, China
Xianghua Zhuang
Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan 250033, China; Multidisciplinary Innovation Center for Nephrology of the Second Hospital of Shandong University, Jinan 250033, China; Correspondence to: The Second Hospital of Shandong University, 247 Beiyuan Street, Jinan 250033, China.
Shihong Chen
Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan 250033, China; Multidisciplinary Innovation Center for Nephrology of the Second Hospital of Shandong University, Jinan 250033, China; Correspondence to: The Second Hospital of Shandong University, 247 Beiyuan Street, Jinan 250033, China.
